Sign up
Pharma Capital

Pharmaxis making strong progress with significant value inflection points ahead

Gary Phillips, chief executive of Pharmaxis Ltd (ASX:PXS) tells Proactive they're continuing to make good progress with their drug development programmes.

After receiving $42 million in milestone payments from Boehringer Ingelheim, the company expects more results later in 2018 which will impact the risk-adjusted valuation of the deal.

Phillips says the NASH study is due to read out in the September quarter and the diabetic retinopathy study in the December quarter this year.

He adds that both studies will provide the first clinical proof of concept in humans and, if positive, would represent a huge step forward in their progress.

The second key event for Pharmaxis will be the mid‐year read out from the phase 1 studies that are underway on their two lead candidates from the anti fibrotic LOXL2 program.


View full PXS profile View Profile
View All

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.